Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

New developments in diagnosis, prognostication, and treatment of advanced systemic mastocytosis
Andreas Reiter, Tracy I. George, Jason Gotlib
Blood (2020) Vol. 135, Iss. 16, pp. 1365-1376
Open Access | Times Cited: 112

Showing 1-25 of 112 citing articles:

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
Joseph D. Khoury, Éric Solary, Oussama Abla, et al.
Leukemia (2022) Vol. 36, Iss. 7, pp. 1703-1719
Open Access | Times Cited: 2535
Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal
Peter Valent, Cem Akin, Karin Hartmann, et al.
HemaSphere (2021) Vol. 5, Iss. 11, pp. e646-e646
Open Access | Times Cited: 204
Carbohydrate-based drugs launched during 2000−2021
Xin Cao, Xiaojing Du, Heng Jiao, et al.
Acta Pharmaceutica Sinica B (2022) Vol. 12, Iss. 10, pp. 3783-3821
Open Access | Times Cited: 150
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia
Eric J. Duncavage, Adam Bagg, Robert P. Hasserjian, et al.
Blood (2022) Vol. 140, Iss. 21, pp. 2228-2247
Open Access | Times Cited: 143
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial
Daniel J. DeAngelo, Deepti Radia, Tracy I. George, et al.
Nature Medicine (2021) Vol. 27, Iss. 12, pp. 2183-2191
Open Access | Times Cited: 106
Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial
Jason Gotlib, Andreas Reiter, Deepti Radia, et al.
Nature Medicine (2021) Vol. 27, Iss. 12, pp. 2192-2199
Open Access | Times Cited: 105
Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized Medicine
Peter Valent, Cem Akin, Bogusław Nedoszytko, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 23, pp. 9030-9030
Open Access | Times Cited: 70
Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User’s Guide for Daily Clinical Practice
Peter Valent, Karin Hartmann, Juliana Schwaab, et al.
The Journal of Allergy and Clinical Immunology In Practice (2022) Vol. 10, Iss. 8, pp. 1999-2012.e6
Open Access | Times Cited: 47
New Insights into the Pathogenesis of Mastocytosis: Emerging Concepts in Diagnosis and Therapy
Peter Valent, Cem Akin, Wolfgang R. Sperr, et al.
Annual Review of Pathology Mechanisms of Disease (2022) Vol. 18, Iss. 1, pp. 361-386
Open Access | Times Cited: 41
Mast cell ontogeny: From fetal development to life‐long health and disease
Shin Li Chia, Simran S. Kapoor, Cyril Carvalho, et al.
Immunological Reviews (2023) Vol. 315, Iss. 1, pp. 31-53
Open Access | Times Cited: 35
Avapritinib versus Placebo in Indolent Systemic Mastocytosis
Jason Gotlib, Mariana Castells, Hanneke Oude Elberink, et al.
NEJM Evidence (2023) Vol. 2, Iss. 6
Open Access | Times Cited: 26
Uncovering two neutrophil-committed progenitors that immediately precede promyelocytes during human neutropoiesis
Ilaria Signoretto, Federica Calzetti, Giulia Finotti, et al.
Cellular and Molecular Immunology (2025)
Open Access | Times Cited: 1
Proposed global prognostic score for systemic mastocytosis: a retrospective prognostic modelling study
Javier I. Muñoz‐González, Iván Álvarez‐Twöse, María Jara‐Acevedo, et al.
The Lancet Haematology (2021) Vol. 8, Iss. 3, pp. e194-e204
Closed Access | Times Cited: 51
Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group
Gregor Hoermann, Karl Sotlar, Mohamad Jawhar, et al.
The Journal of Allergy and Clinical Immunology In Practice (2022) Vol. 10, Iss. 8, pp. 1953-1963
Open Access | Times Cited: 37
Efficacy of avapritinib versus best available therapy in the treatment of advanced systemic mastocytosis
Andreas Reiter, Jason Gotlib, Iván Álvarez‐Twöse, et al.
Leukemia (2022) Vol. 36, Iss. 8, pp. 2108-2120
Open Access | Times Cited: 35
Superior Efficacy of Midostaurin Over Cladribine in Advanced Systemic Mastocytosis: A Registry-Based Analysis
Johannes Lübke, Juliana Schwaab, Nicole Naumann, et al.
Journal of Clinical Oncology (2022) Vol. 40, Iss. 16, pp. 1783-1794
Open Access | Times Cited: 33
The international consensus classification of mastocytosis and related entities
Roos J. Leguit, Sa A. Wang, Tracy I. George, et al.
Virchows Archiv (2022) Vol. 482, Iss. 1, pp. 99-112
Closed Access | Times Cited: 32
Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis
Andreas Reiter, Juliana Schwaab, Daniel J. DeAngelo, et al.
Blood Advances (2022) Vol. 6, Iss. 21, pp. 5750-5762
Open Access | Times Cited: 29
Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry
Vanessa E. Kennedy, Cecelia Perkins, Andreas Reiter, et al.
Blood Advances (2022) Vol. 7, Iss. 9, pp. 1713-1724
Open Access | Times Cited: 28
Secretory and Membrane-Associated Biomarkers of Mast Cell Activation and Proliferation
Roberta Parente, Valentina Giudice, Chiara Cardamone, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 8, pp. 7071-7071
Open Access | Times Cited: 17
Mastocytosis and Mast Cell Activation Disorders: Clearing the Air
Clayton Webster Jackson, Cristina Marie Pratt, Chase Preston Rupprecht, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 20, pp. 11270-11270
Open Access | Times Cited: 40
Avapritinib for advanced systemic mastocytosis
Jason Gotlib, Andreas Reiter, Daniel J. DeAngelo
Blood (2022) Vol. 140, Iss. 15, pp. 1667-1673
Closed Access | Times Cited: 27
Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022
Michel Arock, Gregor Hoermann, Karl Sotlar, et al.
Journal of Allergy and Clinical Immunology (2022) Vol. 149, Iss. 6, pp. 1855-1865
Open Access | Times Cited: 26
Allogeneic haematopoietic cell transplantation for advanced systemic mastocytosis: Best practice recommendations on behalf of the EBMT Practice Harmonisation and Guidelines Committee
Donal P. McLornan, Tomasz Czerw, Gandhi Damaj, et al.
Leukemia (2024)
Closed Access | Times Cited: 5
Cytogenetic and molecular aberrations and worse outcome for male patients in systemic mastocytosis
Hanneke C. Kluin‐Nelemans, Mohamad Jawhar, Andreas Reiter, et al.
Theranostics (2020) Vol. 11, Iss. 1, pp. 292-303
Open Access | Times Cited: 33
Page 1 - Next Page

Scroll to top